Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium Lu 177 LNC1004
- Development stage
- Phase 1
- Lead developer
- Yantai Lannacheng Biotechnology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
lutetium Lu 177 LNC1004 (also known as 177Lu-LNC1004) is an investigational radiopharmaceutical and radioligand therapy targeting fibroblast activation protein (FAP). Developed by Yantai LNC Biotechnology (a subsidiary of Yantai Dongcheng Pharmaceutical Group), the drug consists of an Evans blue (EB)-modified fibroblast activation protein inhibitor (FAPi) conjugated with the chelator DOTA and radiolabeled with the beta-emitting radioisotope lutetium-177 (Lu-177). The Evans blue modification allows the compound to bind reversibly to serum albumin, extending its blood half-life and enhancing tumor accumulation and retention. Upon binding to FAP-expressing cancer-associated fibroblasts (CAFs) in the tumor microenvironment, the radioconjugate is internalized, delivering a localized cytotoxic dose of beta radiation to destroy tumor cells. It is being evaluated in clinical trials for the treatment of FAP-positive advanced malignant solid tumors, including metastatic radioiodine-refractory differentiated thyroid cancer (RAIR-DTC), for which it has received FDA Fast Track designation.
- Other names
- 177Lu-EB-FAPI177Lu-Evans blue-FAP inhibitorlutetium Lu 177-LNC1004
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on lutetium Lu 177 LNC1004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium Lu 177 LNC1004.